Supplementary Methods, Figures 1 - 2 from ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Fan Lin, Olaf van Tellingen(The Netherlands Cancer Institute), Mark C. de Gooijer(Manchester Academic Health Science Centre), Jan H. Beumer(Johns Hopkins University), Levi C.M. Buil(Cancer Genomics Centre), Eloy Moreno Roig(Utrecht University), Thomas Würdinger(Amsterdam University Medical Centers), Jos H. Beijnen(The Netherlands Cancer Institute), Susan M. Christner(Utrecht University)
Cited by 0
Related Papers
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
|The Journal of Experimental Medicine|2007|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial Cells
|Cancer Cell|2008|476
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451